Overview

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers

Status:
Completed

Trial end date:
2014-01-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety, reactogenicity and immunogenicity of 8 different formulations of investigational NTHI vaccine in current and former smokers, 50-70 years of age.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Vaccines